aurinia pharma company profile

The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus Currency in USD. Aurinia Pharma Limited has been running for 14 years. The company is also conducting a Phase 2 clinical trial of voclosporin in focal segmental glomerulosclerosis (FSGS), a rare kidney disease, and is advancin… Excellent is a company building a future focused on growth and innovation, quality products and … Address: Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 2; Compensation: 10. Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs. Aurinia'… Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. February 24, 2021 • 4:02pm EST. Scores indicate decile rank relative to index or region. Latest News. Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences Read Press Release View All News. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 2; Compensation: 10. AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. Company Profile Aurinia Pharmaceuticals Inc. Company Overview. Profile Aurinia Pharmaceuticals Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to … As many as 1.5 million Americans suffer from systemic lupus erythematosus, an autoimmune disease primarily affecting women that causes inflammation in connective tissues. It provides products for patients suffering from serious diseases with a high unmet medical need. Peter S Greenleaf is President/CEO at Aurinia Pharmaceuticals Inc. See Peter S Greenleaf's compensation, career history, education, & memberships. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Find the latest Aurinia Pharmaceuticals Inc (AUPH) stock quote, history, news and other vital information to help you with your stock trading and investing. Benzinga - Mon, 25 Jan 2021 08:30:24 -0400 All rights reserved. Company Number: 05740514 AURINIA PHARMA LIMITED (the "Company") is a Private Limited Company, incorporated on 13 March 2006 (Monday) in UK. Aurinia is advancing voclosporin as a potential best-in-class and first-in-class therapy for the treatment of lupus nephritis (LN) in the U.S. and EU. It provides products for patients suffering from serious diseases with a high unmet medical need. There are currently 4 active directors and 1 active secretary according to the latest confirmation statement submitted on 13th March 2020. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. 12/10/2019. Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of December 3, 2020 is 10. View detailed AUPH description & address. Aurinia’s Response to COVID-19 View. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. Aurinia is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to change the treatment paradigm for patients impacted by rare autoimmune and inflammatory conditions. The Company focuses its development efforts globally. Aurinia Prices US$166.7 Million Public Offering of Common Shares. company provides a diversified range of high quality health care products including those in Cardiology, Gynecology, Neuropsychiatry, Ophthalmology, Diabetes, Nutrition and Dietary supplements. Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. These revenues will be somewhat meaningful for the company. Company Profile and Business Description for Aurinia Pharma Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. See the company profile for Aurinia Pharmaceuticals Inc (AUPH) including business summary, industry/sector information, number of employees, business … The Company’s head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland. The company is headquartered in Victoria, Canada. View real-time stock prices and stock quotes for a full financial overview. Computershare Trust Company of Canada Shareholder Services Dept. So let's talk products, and therefore revenue, first. Aurinia Pharma Limited is an active company incorporated on 13 March 2006 with the registered office located in London, City of London. Company profile for Aurinia Pharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. These revenues will be somewhat meaningful for the company. Aurinia signed a deal for Lupkynis in EU and Japan with Otsuka Pharma last year. Aurinia Pharmaceuticals Inc. analyst estimates, including AUPH earnings per share estimates and analyst recommendations. Company Overview for AURINIA PHARMA LIMITED (05740514) Filing history for AURINIA PHARMA LIMITED (05740514) People for AURINIA PHARMA LIMITED (05740514) More for AURINIA PHARMA LIMITED (05740514) Registered office address C/O Tmf Group 8th Floor, 20 Farringdon Street, London, United Kingdom, EC4A 4AB March 2, 2021 • 6:05am EST. Aurinia has developed voclosporin for the treatment of lupus nephritis. FOUNDED. Learn more about the sector, industry, classification, employee size, and executives of AUPH on MSN … Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. Unity Biotech, Aurinia Among Pharma Companies With R&D Flops in 2020, Stocks: UBX,AMZN,AUPH,ABBV,GSK,RHHBY,ALPMY,PFE,TAK,JNJ,SNY, release date:Dec 18, 2020 Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public … Victoria, BC V8Z 7X8 Canada, NAICS:Pharmaceutical Preparation Manufacturing (325412), SIC:Pharmaceutical and Medicine Industry (3741). See the company profile and updated insider trades of Aurinia Pharmaceuticals Inc. (AUPH). According to the Lupus Foundation of America, up to 60% of those patients will develop lupus nephritis, or an inflammation of the kidneys that, if uncontrolled, can lead to kidney failure and even death. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. Detailed company description & address for Aurinia Pharmaceuticals Inc.. On January 22, the FDA approved Aurinia Pharmaceuticals' Voclosporin to treat Lupus Nephritis, making Aurinia a prime target for some great Pharma in the coming months. The company tested voclosporin against Allergan's former blockbuster Restasis in various FDA-accepted endpoints for dry eye treatments.Aurinia … Aurinia Pharmaceuticals Inc. | 14,119 followers on LinkedIn. Aurinia Pharma shares are trading higher after the company's treatment for Active Lupus Nephritis was approved by the FDA. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. 4464 Markham StreetSuite 1203Victoria, BC V8Z 7X8Canada250 744 2487http://www.auriniapharma.com, Sector(s): HealthcareIndustry: BiotechnologyFull Time Employees: 294. AUPH - key executives, insider trading, ownership, revenue and average growth rates. European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 2020 Virtual Congress Aurinia Pharmaceuticals Inc. 02/2014–04/2019. © 2021 Verizon Media. Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk. Company profile page for Aurinia Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information ... Biotech & Pharma. 100 University Avenue 9th Floor Toronto, ON M5J 2Y1 Canada T: +1-514-982-7555 service@computershare.com #1203-4464 Markham Street Company Profile. The company current operating status is Active and registered office is at C/O TMF GROUP 8TH FLOOR, 20 FARRINGDON STREET, … Lead Director.

Cannavaro Fifa 21 92 Review, Feedback In Urdu, Human Features Of Quebec, Monsieur Klein Streaming, Prince George's County Public Schools Budget, Do The Bidens Have A Cat, All Points East 2020 Massive Attack,